PT - JOURNAL ARTICLE AU - Samuel P Heilbroner AU - Eric P Xanthopoulos AU - Donna Buono AU - Daniel Carrier AU - Ben Y Durkee AU - Michael Corradetti AU - Tony JC Wang AU - Alfred I Neugut AU - Dawn L Hershman AU - Simon K Cheng TI - Efficacy and Cost of High-Frequency IGRT in Elderly Stage III Non-Small-Cell Lung Cancer Patients AID - 10.1101/2020.12.01.20241794 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.01.20241794 4099 - http://medrxiv.org/content/early/2020/12/02/2020.12.01.20241794.short 4100 - http://medrxiv.org/content/early/2020/12/02/2020.12.01.20241794.full AB - Background High-frequency image-guided radiotherapy (hfIGRT) is ubiquitous but its benefits are unproven. We examined the cost effectiveness of hfIGRT in stage III non-small-cell lung cancer (NSCLC).Methods We selected stage III NSCLC patients ≥66 years old who received definitive radiation therapy from the Surveillance, Epidemiology, and End-Results-Medicare database. Patients were stratified by use of hfIGRT using Medicare claims. Predictors for hfIGRT were calculated using a logistic model. The impact of hfIGRT on lung toxicity free survival (LTFS), esophageal toxicity free survival (ETFS), cancer-specific survival (CSS), overall survival (OS), and cost of treatment was calculated using Cox regressions, propensity score matching, and bootstrap methods.Results Of the 4,430 patients in our cohort, 963 (22%) received hfIGRT and 3,468 (78%) did not. By 2011, 49% of patients were receiving hfIGRT. Predictors of hfIGRT use included treatment with intensity-modulated radiotherapy (IMRT) (OR = 7.5, p < 0.01), recent diagnosis (OR = 51 in 2011 versus 2006, p < 0.01), and residence in regions where the Medicare intermediary allowed IMRT (OR = 1.50, p < 0.01). hfIGRT had no impact on LTFS (HR 0.97; 95% CI 0.86 – 1.09), ETFS (HR 1.05; 95% CI 0.93–1.18), CSS (HR 0.94; 95% CI 0.84 – 1.04), or OS (HR 0.95; 95% CI 0.87 – 1.04). Mean radiotherapy and total medical costs six months after diagnosis were $17,330 versus $15,024 (p < 0.01) and $71,569 versus $69,693 (p = 0.49), respectively.Conclusion hfIGRT did not affect clinical outcomes in elderly patients with stage III NSCLC but did increase radiation cost.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to endorse the following potential conflicts of interest: Dr. Wang reports personal fees and non-financial support from AbbVie, non-financial support from Merck, personal fees from AstraZeneca, personal fees from Doximity, personal fees and non-financial support from Novocure, personal fees and non-financial support from Elekta and personal fees from Wolters Kluwer, outside the submitted work; Dr. Cheng reports consulting fees from AbbVie. The other authors have no conflicts of interest.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Columbia University Medical Center IRB approval was granted.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study makes use of the SEER-Medicare database, which is publically available through the NIH.CBCTCone-beam Computer TomographyCIConfidence IntervalCSSCancer-specific SurvivalETFSEsophageal Toxicity Free SurvivalhfIGRTHigh-frequency Image Guided Radiation TherapyIMRTIntensity-modulated RadiotherapyLCDsLocal Coverage DeterminationsLTFSLung Toxicity Free SurvivalNSCLCNon-small-cell Lung CancerOROdds RatiosOSOverall SurvivalSEER-MedicareSurveillance, Epidemiology, And End-Results-Medicare